Lilly plots GLP-1 pill production boost in China, $500M pledge to South Korea
Eli Lilly is making moves in East Asia.
The Indianapolis drugmaker said Wednesday it is earmarking $3 billion over the next decade to increase its manufacturing footprint in China. Earlier this …
FDA Warns Novo Nordisk of Unreported GLP-1 Side Effects
The FDA has issued a warning letter to Novo Nordisk saying the maker of Ozempic and Wegovy failed to report potential side effects in patients who took the medications. The agency cited three deaths among patients, including one who died by suicide. The FDA says the company did not report the deaths within the agency’s required time and that it also failed to investigate or report the suicide.
Novo Hit With FDA Warning Letter for Unreported Ozempic Safety Signals
Among the unreported adverse events potentially linked to Ozempic are two deaths and one case of “completed suicide,” according to an FDA inspection report.
GLP-1 medication changes may support long-term weight management
Patients without diabetes who switched GLP-1 receptor agonist (GLP-1RA) drugs for overweight or obesity were more likely to stick with their treatment longer than those who didn’t switch, according to a new study by UT Southwestern Medical Center researchers. The findings, published in JAMA Network Open, suggest that medication changes are not uncommon among patients undergoing weight loss and that clinicians should encourage them to change GLP-1RAs if necessary to promote continuity of care.
Wegovy may have highest ‘eye stroke’ and sight loss risk among semaglutide GLP-1 agonists
Wegovy, a GLP-1 agonist for weight loss, may carry the highest risk of “eye stroke” (ischemic optic neuropathy) and sudden sight loss of the semaglutide drugs, finds an analysis of unintended side effect reports published in the British Journal of Ophthalmology.
Wegovy users have five times greater risk of sudden sight loss than Ozempic users, study finds
‘Eye strokes’ that reduce blood flow to optic nerve likely to be side-effect of active ingredient semaglutide, says authorPatients taking Wegovy have nearly five times the risk of sudden sight loss of those on Ozempic, a large-scale study has found.Glucagon-like peptide-1 receptor agonist (GLP-1 RA) medicines such as semaglutide (sold as Wegovy, Ozempic and Rybelsus) and tirzepetide (sold as Mounjaro) help reduce blood sugar levels, slow digestion and reduce appetite, and have been linked to reduced risks of heart attack, fewer drug overdoses and other health benefits. Continue reading…
Tale of Two Drugs: Wegovy Linked to Higher Risk of Blinding Eye Stroke vs Ozempic
(MedPage Today) — The obesity drug semaglutide (Wegovy) conferred a significantly higher risk of ischemic optic neuropathy (ION) than any other GLP-1 agonist, including semaglutide for diabetes (Ozempic), an analysis of FDA data showed.
In a…
FDA warns Novo Nordisk of potential unreported GLP-1 side effects
The FDA issued a warning letter to Novo Nordisk — the maker of Ozempic and Wegovy — for failing to report potential side effects in patients who took its blockbuster medications.
The Ultimate Grocery List for GLP-1 Users, According to a Dietitian
These kitchen staples are nutrient-dense and easy to tolerate.
FDA warns Novo Nordisk over unreported potential Ozempic side effects
The FDA issued a warning letter to Novo Nordisk, the Danish drugmaker behind the diabetes and weight-loss medications Ozempic and Wegovy, over unreported potential side effects.